期刊
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
卷 76, 期 2, 页码 239-240出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.diagmicrobio.2013.01.002
关键词
Dalbavancin; Rarer species; beta-Streptococci; Viridans group; Lipoglycopeptides; ABSSSI
Dalbavancin is an investigational lipoglycopeptide having an extended serum elimination half-life allowing once-weekly dosing. Data from testing 1357 strains of uncommonly isolated species expand the dalbavancin spectrum details as follows (MIC50/90): beta-haemolytic streptococcal serogroups C, F, and G (<= 0.03/<= 0.03 mu g/mL), 7 viridans group of streptococci (<= 0.03/<= 0.03-0.06 mu g/mL), 5 Corynebacterium spp. (0.06/0.12 mu g/mL), Listeria monocytogenes (0.06/0.12 mu g/mL), and Micrococcus spp. (<= 0.03/<= 0.03 mu g/mL). Among all reported isolates, 99.8% of tested strains were inhibited at dalbavancin MIC values at <= 0.12 mu g/mL. Dalbavancin remains very potent against rarer Gram-positive pathogens, using in vitro test experience with organisms cultured through 2011. (C) 2013 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据